| dc.contributor.author | Kavadichanda, Chengappa | |
| dc.contributor.author | Ahmed, Sakir | |
| dc.contributor.author | Pakhchanian, Haig | |
| dc.contributor.author | Gupta, Latika | |
| dc.contributor.author | Kardes, Sinan | |
| dc.contributor.author | Raiker, Rahul | |
| dc.date.accessioned | 2021-12-10T12:42:58Z | |
| dc.date.available | 2021-12-10T12:42:58Z | |
| dc.identifier.citation | Raiker R., Pakhchanian H., Kavadichanda C., Gupta L., Kardes S., Ahmed S., "Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network", CLINICAL RHEUMATOLOGY, 2021 | |
| dc.identifier.issn | 0770-3198 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_d17994e4-086a-46dc-bc32-75feaebebd0d | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/174490 | |
| dc.identifier.uri | https://doi.org/10.1007/s10067-021-05979-y | |
| dc.description.abstract | Introduction The outcomes of COVID-19 in patients with axial spondyloarthritis (ax-SpA) have not been explored in detail. Tumour necrosis factor inhibitors (TNFi) are commonly used for ax-SpA patients, and how they influence outcomes may have implications on COVID-19 management. | |
| dc.language.iso | eng | |
| dc.subject | İmmünoloji ve Romatoloji | |
| dc.subject | Rheumatology | |
| dc.subject | Health Sciences | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ROMATOLOJİ | |
| dc.title | Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network | |
| dc.type | Makale | |
| dc.relation.journal | CLINICAL RHEUMATOLOGY | |
| dc.contributor.department | College Of West Virginia , , | |
| dc.contributor.firstauthorID | 2772309 | |
